Capsule Endoscopy in Newly Diagnosed Patients of Celiac Disease

Extent of Small Bowel Involvement on Capsule Endoscopy in Newly Diagnosed Patients of Celiac Disease

Patrocinadores

Patrocinador principal: Tazeen Rasheed

Fuente Dow University of Health Sciences
Resumen breve

Celiac Disease is an autoimmune disorder that affects approximately 1% of the world's population 1. The diagnosis of CD requires clinical, histopathological and serological factors 2. Since upper gastrointestinal endoscopy allows only visualization of the small bowel up to the second part of duodenum therefore this study was designed to determine involvement of different segments of small bowel using endoscopic scale by Bonatto MW et al 3 in newly diagnosed patients of celiac disease.

Descripción detallada

This cross sectional observational study will take place in Medical Unit-II Ruth KM Pfau Civil Hospital Karachi, Pakistan. All newly diagnosed patients of celiac disease between the ages of 8 & 60 years and patients who are currently not on gluten free diet will be included.

Patients having intestinal obstruction, strictures, fistulae, dysphagia, pregnant females will be excluded. Patients having cardiac pacemakers or other implanted electromedical devices and those who are unable to swallow the capsule will also be excluded.

All patients meeting inclusion criteria will be included. Informed consent will be taken from ethics committee. Patients will be provided proper brief information of procedure and confidentiality of the patients will be ensured. Patients will be advised to start clear liquid diet for 24 hours before the procedure. They will be advised to drink Movcol powder 10 sachet in 500ml of water within 20 mins, 12 hours before the procedure. They will be kept nil orally for 08 hours before the procedure. Syrup Infacol (simethicone) 15ml diluted in 50 ml of water will be given 30 mins before the procedure. Patients will be asked to swallow the capsule with 200 ml of water. Patients will be allowed to take food 4 after ingestion of capsule. All patients will be provided with capsule retrieval kit from stool. Patients will be explained to pass any stool after ingestion of capsule till it passed in stool or up to 7 days whichever is earlier. Capsule retrieved will be brought back to investigators for data retrieval from capsule. Reporting will be done by person trained to interpret capsule endoscopy. This will include presence of any pathology, its severity, approximate length and segment of small intestine involved and quality of bowel preparation.

Categorical data will be presented as frequency and percentage, e.g., gender, findings of capsule endoscopy like, bowel preparation, mosaic pattern,ulcers, erythema, telangiectasia etc. Quantitative data will be presented as mean with standard deviation, e.g., age. Involvement of different segments of small intestine (duodenum, jejunum and Ileum) will be documented. Categorical data will be compared on gender by Chi-square test and quantitative data will be analyzed by student's t-test. Significance level will be set at ≤0.05.

Estado general Not yet recruiting
Fecha de inicio December 2018
Fecha de Terminación December 2019
Fecha de finalización primaria November 2019
Tipo de estudio Observational
Resultado primario
Medida Periodo de tiempo
Grading of Celiac Disease on Capsule Endoscopy using Bonatto Classification 8 hours
Inscripción 30
Condición
Elegibilidad

Método de muestreo: Non-Probability Sample

Criterios:

Inclusion Criteria:

1. All newly diagnosed patients of celiac disease between the ages of 8 & 60 years.

2. Patients who are currently not on gluten free diet.

Exclusion Criteria:

1. Patients having intestinal obstruction, strictures, fistulae, dysphagia will be excluded.

2. Pregnant females will be excluded.

3. Patients having cardiac pacemakers or other implanted electromedical devices.

4. Unable to swallow capsule.

Género: All

Edad mínima: 8 Years

Edad máxima: 60 Years

Oficial general
Apellido Papel Afiliación
Bader F Zuberi, FCPS Study Chair Dow University of Health Sciences
Contacto general

Apellido: Tazeen Rasheed, FCPS

Teléfono: 0332-3826761

Email: [email protected]

Ubicación
Instalaciones: Ruth KM Pauf Civil Hospital
Ubicacion Paises

Pakistan

Fecha de verificación

November 2018

Fiesta responsable

Tipo: Sponsor-Investigator

Afiliación del investigador: Dow University of Health Sciences

Nombre completo del investigador: Tazeen Rasheed

Título del investigador: Assistant professor

Palabras clave
Tiene acceso ampliado No
Condición Examinar
Datos del paciente No
Información de diseño del estudio

Modelo de observación: Case-Only

Perspectiva de tiempo: Cross-Sectional

Fuente: ClinicalTrials.gov